EUVIMEDEUVIMED entdecken
Crossref

US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience

Kimberly A Smith iD, Yin Huang iD, Theresa Kehoe iD, Stefanie Kraus, Mark Levenson iD, Jie Li, Kristen Miller, Ann Punnoose iD, Donna R Rivera iD, Yueqin Zhao, Richard Forshee iD, John Concato iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Kimberly A Smith und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Evidence-Based Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug ApprovalEvidence-Based MedicineUnited StatesHumans

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Kimberly A Smith, Yin Huang, Theresa Kehoe, Mark Levenson, Ann Punnoose, Donna R Rivera, Richard Forshee, John Concato

Zitieren

APA

Smith, K. A., Huang, Y., Kehoe, T., Kraus, S., Levenson, M., Li, J., Miller, K., Punnoose, A., Rivera, D. R., Zhao, Y., Forshee, R., & Concato, J. (2025). US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3700

Vancouver

Smith KA, Huang Y, Kehoe T, Kraus S, Levenson M, Li J, et al. US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3700

BibTeX
@article{Smith2025,
  author = {Smith, Kimberly A and Huang, Yin and Kehoe, Theresa and Kraus, Stefanie and Levenson, Mark and Li, Jie and Miller, Kristen and Punnoose, Ann and Rivera, Donna R and Zhao, Yueqin and Forshee, Richard and Concato, John},
  title = {US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3700}
}
Kostenlos starten →